Apollomics (APLM) Q2 2025 earnings summary

Executive summary

• Reported financial results for the first half of 2025, focusing on oncology drug development and clinical progress.

• Lead program vebreltinib (APL-101) is in Phase 2 multicohort clinical trials targeting c-Met alterations in cancer.

Financial highlights

• Cash, cash equivalents, and marketable funds were $2.1 million as of June 30, 2025, down from $9.8 million at year-end 2024.

• R&D expenses decreased to $4.6 million (including $0.8 million share-based compensation) from $16.9 million (including $3.7 million share-based compensation) year-over-year.

• General and administrative expenses rose to $14.5 million (including $2.5 million share-based compensation) from $10.2 million (including $4.5 million share-based compensation) year-over-year.

• Net loss for the first half of 2025 was $12.5 million, or $11.37 per share, compared to $35.2 million, or $37.53 per share, in the first half of 2024.

• Revenue for the period was $8.5 million, with other income of $83, and total comprehensive loss of $12.5 million.

Outlook and guidance

• Cash position is projected to fund planned operations into the third quarter of 2026.